AnteoTech partners with global life sciences company to develop CLIA product using AnteoBind NXT technology
AnteoTech Limited (ASX: ADO) has signed an agreement and commenced an Initial Work Program with a large global life sciences company to develop an activated particle product targeting the US$13 billion chemiluminescent immunoassays (CLIA) market. This Anteotech AnteoBind NXT CLIA Development represents a strategic move to nearly double the company’s addressable market beyond its current lateral flow and other platforms segments, which are valued at approximately US$15.5 billion.
Under the agreement, AnteoTech will receive A$64,500 for services and materials through a 50:50 shared cost contract. The Initial Work Program is scheduled for completion by the end of FY 2026. Successful completion of defined technical and commercial milestones is expected to progress the parties toward a joint product development agreement for CLIA market entry, either through combined product commercialisation or direct supply arrangements.
The CLIA market represented 23% of the overall in vitro diagnostics (IVD) immunoassays market in 2024, which was valued at approximately US$56 billion. The CLIA segment is forecast to grow at approximately 6% CAGR through to 2029. Entry into this market would position AnteoTech to capture greater commercial value by transitioning from a performance additive supplier to a provider of core ingredients in ready-to-use, fully integrated diagnostic products.
Merrill Gray, Managing Director & Chief Executive Officer
“This agreement reflects the strength of our large global life sciences company re-engagement strategy and supports our objective of moving AnteoBind NXT further up the value chain. We look forward to advancing this relationship and progressing a new product opportunity that has the potential to support sales growth in additional immunoassay markets.”
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
What is CLIA and why does it matter for diagnostics?
Chemiluminescent immunoassays (CLIA) have become a backbone technology in clinical diagnostics. CLIA platforms are used for detection and quantification of hormones, infectious disease markers, cardiac biomarkers and tumour markers. Their high sensitivity, broad dynamic range and compatibility with automated platforms make them well suited to applications requiring rapid, accurate and reproducible detection of proteins, antibodies and other biological molecules.
Magnetic particles are central to high throughput, fully automated CLIA platforms used in today’s clinical laboratories. The global IVD immunoassay market was valued at approximately US$56 billion in 2024, with CLIA representing US$13 billion or 23% of that market. AnteoTech currently participates in the lateral flow and other platforms segments, valued at approximately US$15.5 billion in 2024, representing 28% of the immunoassays market.
For investors, CLIA’s significance lies in its market scale and growth trajectory. The 6% CAGR projected through 2029 offers a stable, expanding addressable market. Successful entry would nearly double AnteoTech’s participation in the immunoassays sector, potentially supporting meaningful revenue diversification beyond the company’s existing lateral flow focus.
AnteoBind NXT delivers significant performance advantages over existing technologies
Current CLIA technologies face limitations that create commercial opportunities for improved solutions. EDC/NHS chemistry and Tosyl chemistry, the most widely used coupling methods, result in random antibody orientation on magnetic particles. This random attachment means antibody binding sites can face the particle surface, rendering them unavailable to capture target antigens. The outcome is reduced assay sensitivity and increased reagent consumption.
AnteoBind NXT addresses these limitations through preferential antibody binding. The technology preserves the accessibility of antigen-binding sites on antibody molecules, increasing the proportion of functionally active antibodies on the particle surface. In-house testing has demonstrated that AnteoBind NXT requires up to six times lower antibody usage compared to Tosyl chemistry to achieve equivalent assay sensitivity.
This performance improvement carries direct cost implications. Capture antibodies can account for up to 35% of total assay costs. Reducing antibody consumption by up to six times could deliver substantial cost reductions for diagnostic manufacturers and clinical laboratories. A technical white paper outlining these test results is being finalised for release.
Technical comparison: AnteoBind NXT versus Tosyl chemistry
| Feature | Tosyl Chemistry | AnteoBind NXT |
|---|---|---|
| Antibody usage | Higher | Up to 6x lower |
| Antibody orientation | Random | Preferential (preserved binding sites) |
| Incubation time | Extended (often overnight) | Improved |
| Assay sensitivity | Variable due to orientation issues | Enhanced through active binding sites |
Performance enhancement and cost reduction are critical drivers in CLIA market adoption. Researchers require ease of use, greater sensitivity and specificity, while laboratory managers and procurement teams prioritise cost efficiencies. AnteoBind NXT’s demonstrated performance could position it as a key ingredient in next-generation CLIA products if the Initial Work Program progresses successfully.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
Strategic pathway and what comes next for AnteoTech
This agreement follows the company’s December 2025 Life Sciences update, which outlined progress against the June 2025 Strategic Review. That update highlighted the latest order from Serum Institute of India (SII), new AnteoBind NXT sales and a record number of evaluations currently underway. The company’s re-engagement strategy with large global life sciences companies builds on longstanding relationships and technical expertise in the sector.
The Initial Work Program formalises collaboration with a global particle manufacturing partner that has a significant, well-established customer base and distribution network. This partner’s existing market presence could accelerate commercial adoption if technical milestones are achieved.
For investors, the strategic significance lies in the value chain positioning. AnteoTech is transitioning from a performance additive supplier to a provider of core ingredients in ready-to-use products. This shift could support improved margins and larger contract values compared to additive supply arrangements.
- Complete Initial Work Program by end of FY 2026
- Achieve defined technical and commercial milestones
- Progress to joint product development agreement
- Target CLIA market entry through combined product commercialisation or direct supply
The US$13 billion CLIA market represents approximately 23% of the overall IVD immunoassays market. Entry into this segment would expand AnteoTech’s addressable market beyond lateral flow and other platforms, potentially supporting sales growth across additional immunoassay segments. The company’s objective is for AnteoBind NXT activated magnetic particles to achieve performance levels that will support broad adoption within the CLIA market on automated immunoassay platforms.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving announcements hit the ASX.